LIFEGARD II

PEABODY, MASS. (June 27, 2005) – Analogic Corporation (NASDAQ: ALOG) announced today that the U.S. Food & Drug Administration (FDA) has given market clearance for the LIFEGARDTM II family of non-invasive patient monitors.

The LIFEGARD II is the latest in a series of non-invasive patient monitors from Analogic. LIFEGARD II is the platform upon which the Company will expand its patient monitoring offerings. The first release consists of five models. The basic units measure five parameters, while other models also monitor continuous non-invasive cardiac output and end-tidal CO2. Units come equipped with integrated printers for recording waveform and parameter values. The first models of LIFEGARD II are scheduled to be released this summer and additional models with cleared capabilities are to be made available over the next 18 months.

Lonnie Weaver, General Manager of Analogic’s Life Care Systems Division, noted, “The LIFEGARD II represents a significant expansion of our growing LIFEGARD family of non-invasive patient monitors. The non-invasive, portable LIFEGARD II family adds a new level of versatility to patient monitoring by allowing clinicians to comprehensively monitor patients anywhere in the hospital or in non-acute environments such as a freestanding clinic or physician’s office. Clinicians can evaluate a patient in considerably less time and with no risk of infection, compared to conventional monitoring modalities.”

For more information on the new LIFEGARD II family of non-invasive patient monitors, visit www.analogic.com/lifegard or call 800-599-7769.

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold primarily to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing.